Nevertheless, it could be highly suggestive of a parallelism between the peripheral vascular effects of SGLT2-i on clinical outcomes related to DFS, such as reduction in amputation rate, rehospitalization, and infection, and also of the impacts on cardiovascular morbidity that have underlined the role of DFS as a cardiovascular risk indicator in diabetics [9]. Here, SLC5A2 is linked to infection.